Claritev Corp SEC Filings

Prince John Michael reported acquisition or exercise transactions in this Form 4 filing.

Claritev Corp director Prince John Michael received an equity grant of Class A common stock. On April 29, 2026, he was awarded 8,977 restricted stock units at a stated price of $0.00 per share, increasing his directly held position to 21,662 shares.

The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the next regularly scheduled annual meeting of stockholders, subject to continued service. If he voluntarily resigns (other than for cause), the units vest pro rata based on days of service.

Colaluca Anthony Jr reported acquisition or exercise transactions in this Form 4 filing.

Claritev Corp director Anthony Jr. Colaluca received a grant of 8,977 shares of Class A common stock as restricted stock units. The award was made at a price of $0.00 per share, increasing his directly held Class A common stock to 24,334 shares.

The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the next regularly scheduled annual meeting of stockholders, subject to continued service. If he voluntarily resigns (without grounds for termination for cause), the units vest on a pro rata basis based on days of service. He also indirectly holds 5,500 shares through a trust.

Claritev Corporation held its Annual Meeting on April 29, 2026, where stockholders approved an amendment to the 2020 Omnibus Incentive Plan that increases the common stock reserved under the plan by an additional 2,375,000 shares. Stockholders also elected four Class III directors to the Board and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026. In advisory voting, stockholders approved the compensation of the named executive officers and supported the incentive plan amendment, indicating broad backing for the company’s current governance and compensation structure.

Albinson Brock reported acquisition or exercise transactions in this Form 4 filing.

Claritev Corp senior vice president and chief accounting officer Albinson Brock received a grant of 2,956 restricted stock units tied to Class A common stock. These units were awarded at no cash cost as part of his compensation.

The RSUs will vest in four equal installments of 25% each on March 31 of 2027, 2028, 2029, and 2030, aligning incentives over several years. After this award, Brock directly holds 30,193 shares of Claritev common stock.

Claritev Corporation is calling a virtual annual meeting on April 29, 2026 for holders of Class A stock as of March 6, 2026. Stockholders are being asked to elect four Class III directors, ratify PricewaterhouseCoopers LLP as auditor, approve executive pay on an advisory basis, and approve an amendment increasing shares under the 2020 Omnibus Incentive Plan.

Claritev positions itself as a healthcare technology, data and insights company focused on transparency and affordability. Management highlights a 2025 “Year of the Turn,” returning to revenue growth, stronger adjusted EBITDA and free cash flow, and more than $67 million in new annual contract value. The company processed $179.8 billion in medical charges, identifying $25.0 billion in potential cost savings, and reports 2025 total stockholder return of 189%.

The executive pay program centers on market-competitive salaries, annual cash incentives and equity awards. 2025 bonuses paid at 110% of target after the leadership team requested negative discretion to shift more of the pool to other employees. From 2026, 25% of long-term incentives for executives will be performance stock units tied to unlevered free cash flow. The proxy also details a classified 11-seat board with a lead independent director, extensive healthcare and technology experience, and committee oversight of risk, including cybersecurity and artificial intelligence, alongside a sustainability working group and plans for a 2025 Corporate Responsibility Report in the third quarter of 2026.

Claritev Corporation used its 2026 Investor Day to outline its strategy, financial guidance, and long-term goals for its healthcare cost-management and analytics platform. Management highlighted core businesses in claims intelligence, network solutions, and payment and revenue integrity, plus growth in data and analytics, international markets, and services.

For FY 2026, Claritev projects revenue of $980 million to $1 billion and Adjusted EBITDA of $605 million to $615 million, with total capital spend of $160 million to $170 million, an effective tax rate of 24% to 28%, and free cash flow of $0 to $10 million.

The company’s Vision 2030 model contemplates revenue of $1.3 billion and Adjusted EBITDA of $800 million, targeting an Adjusted EBITDA margin of roughly 61% to 64% and a path to reduce net leverage toward about 5.0x while increasing levered free cash flow.

Claritev Corp executive vice president and CFO Garis Douglas Michael bought shares of his company in the open market. On March 16, 2026, he purchased 1,300 shares of Class A common stock at $17.69 per share, bringing his direct holdings to 206,152 shares.

He also reports indirect ownership of additional Class A shares through retirement accounts, including 19,927 shares in his spouse's IRA and 45,810 shares in his own IRA, along with smaller positions in IRAs for his daughter and son. The filing shows a net-buy transaction with no reported sales.

Claritev Corp executive vice president and Chief Digital Officer Kim Michael bought 15,000 shares of Class A common stock in an open-market transaction at $16.50 per share on 2026-03-12, increasing direct ownership to 182,878 shares.